Alcon Acquired by Novartis
On December 15, 2010, Novartis (NYSE: NVS) agreed to acquire the remaining shares of Alcon, Inc. (NYSE: ACL) it doesn't currently own for $168 per share.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
View Older Stories View More Recent Stories
-
ThromboGenics Business Update - Q3 2016
-
Leanplum Raises $29M Series C Round Led By Canaan Partners; Expands Mobile Engagement Channels With Email
-
Alcon launches the CyPass® Micro-Stent at the American Academy of Ophthalmology (AAO) 2016 annual meeting
-
Fruit-Rich Mediterranean Diet with Antioxidants May Cut Age-Related Macular Degeneration Risk by More than a Third
-
Latest ThromboGenics' Clinical Data to be Presented at 2016 American Academy of Ophthalmology (AAO) Meeting in Chicago
-
Novaliq Strengthens Executive Management Team by Appointing Christian Roesky, PhD, as Chief Executive Officer
-
iOmx Therapeutics raises EUR 40 million in Series A round
-
Daily Report Selects Greenberg Traurig as 2016 Litigation Department of the Year Winner
-
Avedro Appoints Dr. Reza Zadno As Chief Executive Officer
-
Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience
-
Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience
-
Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience
-
Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience
-
Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience
-
Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience
-
Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience
-
Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience
-
Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience
-
Alcon launches the NGENUITY® 3D Visualization System designed to further enhance retinal surgeon experience
-
ThromboGenics Presenting New Ophthalmic Research Data
-
Valeant Pharma (VRX) Announces Key Management Changes; Includes New Business Strategy SVP
-
Valeant Pharmaceuticals Announces Changes To Executive Management Team
-
Apellis Pharmaceuticals Announces Appointment of Dr. Robert Kim as Chief Medical Officer
-
pSivida (PSDV) Appoints New Chief Medical Officer
-
pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer
-
Glaukos Corporation (GKOS) Raising PT After Blowing Out Numbers - Cantor Fitzgerald
-
Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
-
Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
-
Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
-
Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
-
Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
-
Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
-
Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
-
Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
-
Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
-
Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
-
Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma
-
Notal Vision Appoints Dr. Susan Orr as Chief Medical Officer and Vice President of Medical Affairs
-
Guidepost Solutions Appoints Sokolow Former Novartis Services General Counsel
-
Novartis (NVS) Tops Q2 EPS by 5c; Cautions on Entresto Spending
-
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
-
Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
-
Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
-
Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
-
Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
-
Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
-
Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
-
Novelis Appoints Devinder Ahuja as Senior Vice President, Chief Financial Officer
-
Novartis (NVS) Updates on Outlook into 'Meet Management' Event
-
Novartis willing to sell Roche stake without demanding premium - CEO
